Improved Drug Susceptibility Testing (DST) for Mycobacteria
Forecasted Federal grant Posted
- Opportunity number
- RFA-AI-28-018
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Applications expected due
- Award size
- Not on record
Opportunity facts
- Expected posting
- Assistance listings
- Funding instrument
- Cooperative Agreement
- Category
-
- Health
- Eligible applicants
-
- Tribal Organizations (Not Federally Recognized)
- City/Township Governments
- Non-501(c)(3) Nonprofits
- Other
- Higher Education Inst. (Public)
- For Profit Organizations
- 501(c)(3) Nonprofits
- State Governments
- Small Businesses
- Tribal Governments (Federally Recognized)
- Independent School Districts
- Higher Education Inst. (Private)
- County Governments
- Public or Indian Housing Auth.
- Special District Governments
- Points of contact
Opportunity details come from Grants.gov. Updated .
About this opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) seeks applicants to support research developing improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those used to treat tuberculosis and non-tuberculous mycobacterial infections, as a cooperative agreement under CFDA 93.855 (Allergy and Infectious Diseases Research). This is a forecast; no application deadline is specified.
NIAID will fund innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Current culture-based assays are slow and impede rapid testing of mycobacterial strains and their drug susceptibility. The program addresses urgent public health needs: TB is a leading infectious disease killer worldwide, drug-resistant TB strains are increasing, NTM lung disease rates are rising in the United States (especially among women and older adults), and TB cases have reached their highest level in ten years.
Eligible applicants include state governments, county governments, city and township governments, Native American tribal governments (federally and non-federally recognized), higher education institutions (public and private), 501(c)(3) and non-501(c)(3) nonprofits, for-profit organizations, small businesses, special district governments, public or Indian housing authorities, independent school districts, faith-based and community-based organizations, regional organizations, U.S. territories or possessions, and non-domestic (foreign) entities.
All applications undergo peer review for scientific merit and technical adequacy by an appropriate initial review group and the National Advisory Allergy and Infectious Diseases Council. Evaluation criteria assess scientific significance, experimental design adequacy, investigator competency, facility and resource adequacy, budget justification relative to project scope, and relevance to program objectives. Awards are subject to HHS inspection and audit under 2 CFR 300, with recipients required to retain financial and programmatic records for three years from the date the annual financial status report is submitted.
Forecast synopsis
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance its mission by supporting research to develop improved drug susceptibility tests (DSTs) for mycobacterial drugs, including those currently used for treatment of tuberculosis (TB) and clinically important non-tuberculous mycobacterial (NTM) infections, new drugs and drugs in late-stage clinical development. TB is a leading cause of death from an infectious disease worldwide and drug-resistant strains of TB, including those resistant to new drug regimens, are increasing. In the United States, rates of NTM lung disease are rising, especially among women and older adults, while TB cases have surged to their highest level in ten years. Current assays utilize slow, culture-based processes that do not allow for the rapid testing of mycobacterial strains and their drug susceptibility. Improved DSTs are essential for guiding effective treatment, reducing drug-resistant mycobacterial rates, and preventing new transmissions. This program will support the development of innovative DST assays, including rapid genotypic and improved phenotypic methods that do not require full culture growth. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity